VRTX241227P440000
- 30.00
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Weekly Buzz: So far, Santa is Letting us Down
Friday Market Pulls Back, Led by Mag Seven Decline | Live Stock
10 Health Care Stocks With Whale Alerts In Today's Session
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): 'This Is Hardly Down For The Year. I Think It Can Still Go Lower'
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Vertex Pharmaceuticals Price Target Lowered to $460 From $550 at Truist
Truist has lowered the Vertex Target Price to 460 dollars.
Truist: lowered the Target Price of Vertex Pharmaceuticals from $550 to $460, maintaining a Buy rating. (Gelonghui)
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank